Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for Severe COVID-19
NCT04411602Phase 1Withdrawn
- Sponsor
- Henry Ford Health
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19), sponsored by Henry Ford Health. Primary endpoint: Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure at 28 days. Planned start Apr 2020; status: withdrawn.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04411602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411602.